

AUTHOR INDEX

VOLUME 25

- Ackerman, Bruce H., 785
 Ackers, Irene, 579
 Actor, P., 373
 Actor, Paul, 694
 Adejuyigbe, Olusanya, 497
 Adkinson, N. Franklin, Jr., 93
 Ahmed, S. Masud, 643
 Akhter, S. Q., 643
 Albritton, William L., 187, 296
 Alford, Robert H., 405
 Anderson, Burt, 296
 Andreana, Augusto, 182
 Andrews, J. M., 612
 Andritz, Mary H., 33
 Angehrn, Peter, 607
 Apolloni, E., 760
 Arbeter, A. M., 417
 Arceneaux, Jean E. L., 650
 Arcey, Sergio M., 16
 Arndt, Kenneth A., 553
 Aronoff, George R., 513
 Aronoff, Stephen C., 279
 Arosio, E., 760
 Asahi, Yoshinari, 131
 Ash, Ronald J., 443
 Assael, Baroukh M., 395
 Auerbach, Jeffrey I., 622
 Auger, François, 662
 Austin, Thomas W., 455
 Ayers, L. W., 633
 Ayers, Leona W., 669
 Ayrton, John, 78
 Azegami, Masao, 146
- Baba, Masanori, 515
 Baker-Zander, Sharon A., 390
 Ballard, James O., 153
 Baltch, Aldona L., 33, 488
 Bannatyne, Robert M., 537
 Barge, Janine, 168
 Barlam, Tamar, 529
 Barnes, Scott G., 153
 Baron, Ellen J., 781
 Baron, Jody L., 646
 Baron, Samuel, 646
 Barrueco, M., 458
 Barry, A. L., 633
 Barry, Arthur L., 392, 669, 710, 775
 Bartus, Henry R., 622
 Barza, Michael, 655
 Baxter, Heather, 306
 Bayer, Arnold S., 725
 Beaulieu, Bernard B., Jr., 65
 Bedows, Elliott, 719
 Beggs, William H., 316
 Beight, Douglas W., 443
 Belshim, Judy, 179
 Benoni, G., 760
 Berens, Randolph L., 292
 Berliner, Daniel, 7
 Berman, Steven J., 438
 Bianchi, P., 666
 Biddle, James, 296
 Bieth, Gilda, 289
 Blase, David K., 513
 Blevins, Roger D., 603
 Blok-Perkowska, Danuta, 134
 Blomqvist, Charlotte, 179
 Blumer, Jeffrey L., 579
 Bondi, Joseph V., 238
- Bongaerts, Ger P. A., 234
 Borner, K., 105
 Borobio, M. Victoria, 342
 Borowski, E., 772
 Borsa, F., 638
 Bosso, John A., 630
 Boutwell, M. E., 650
 Bouzos, John, 534
 Bright, Gene M., 113
 Brion, Nils, 168
 Brook, Itzhak, 71
 Brown, Daniel R., 422
 Brown, Douglas, 286
 Brown, Timothy H., 405
 Brumfit, W., 276
 Bryan, C. S., 37
 Bryan, L. E., 382, 747
 Buesing, Mary A., 283
 Butler, Thomas, 643
 Buu-Hoi, Annie, 289
 Byers, B. R., 650
- Cabezudo, Ignacio, 4
 Cable, Douglas C., 258
 Campbell, Gwendolyn S., 205
 Campos, Jose, 706
 Campos, Joseph M., 327
 Carbon, Claude, 168, 618
 Cardinal, J. R., 10
 Carr, Douglas, 539
 Carter, Walker T., 162
 Casalino, M., 499
 Catlin, B. Wesley, 676
 Chan Lee, Huei, 146
 Chau, Nguyen Phong, 618
 Cheung, Rose, 537
 Chiemchanya, Surang, 273
 Chin, Nai-Xun, 319, 687
 Chopra, Ian, 446
 Chou, Sunwen, 25
 Cohn, Naomi K., 292
 Coleman, William G., Jr., 539
 Collins, Shirley H., 301
 Comanducci, A., 499
 Congeni, Blaise L., 40
 Conroy, Joseph V., 33
 Contrepois, Alain, 168, 618
 Coolbaugh, James C., 71
 Coppenhaver, Dorian H., 466
 Correia, Ricardo A., 653
 Crooke, Stanley T., 622
 Crossley, Kent B., 532
 Crumacker, Clyde S., 247, 553
 Culbert, Steve, 62
- Daneshmendi, Tawfik K., 1
 Davidson, Bruce A., 719
 Davies, Mary-Ellen M., 238
 Davis, Donald R., 20
 De Broe, Marc E., 783
 De Clercq, Erik, 566
 De Clercq, Erik, 515
 DeGirolami, P., 401
 Deneer, Harry G., 187
 Denoya, Claudio D., 659
 Devlin, Richard G., 358
 Devos, J., 764
 Dewsnup, Daniel H., 165
 Dilillo, Mariantonia, 182
 Diven, Warren, 473
 Dominguez-Gil, A., 458
- Dotzla, Joe E., 216
 Dromer, Françoise, 168
 Dubois, Catherine, 168
 Dubreuil, L., 764
 Dunn, George L., 694
 Dworack, David L., 494
 Dylewski, Joe S., 25
- East, Donald S., 83
 Eby, George A., 20
 Echols, Roger M., 336
 Egbert, Peter R., 25
 Eisenstadt, Rosalee, 725
 Elion, Gertrude B., 507
 Eliopoulos, G. M., 331, 401
 Eliopoulos, George M., 398
 Elvers, A., 105
 Ene, Mokelu D., 1
 Eng, Robert H. K., 510
 English, A. R., 118
 English, Arthur R., 113, 226, 599
 Eppstein, Deborah A., 563
- Fadl-Allah, Nora, 375
 Fainstein, V., 387
 Falkinham, Joseph O., III, 137
 Farber, Bruce F., 398
 Fasching, Claudine E., 58, 545, 596
 Fass, Robert J., 408
 Field, A. Kirk, 238, 247
 Fillastre, J. P., 638
 Finegold, Sydney M., 162
 Fischer, Philip R., 502
 Fite, Laurie D., 443
 Fliegelman, Robert M., 504
 Florioli, Alessandra, 395
 Flynn, Gary A., 443
 Foglesong, Mark A., 216
 Fontijne, P., 575
 Forbes, Betty A., 491
 Forthal, Donald N., 258
 Fortin, Louise, 83
 Fourtillan, Jean-Bernard, 618
 Frankel, Lawrence S., 62
 Fraser-Smith, Elizabeth B., 563
 Freydière, A. M., 144
 Frongillo, R. F., 666
 Fuchs, Peter C., 392
 Funk, Mary L., 301
 Furman, Phillip A., 191, 507
- Gangemi, J. D., 37
 Garcia-Tornel, Santiago, 706
 Gardella, A., 331, 401
 Gavan, Thomas L., 669
 Gaynon, Michael W., 25
 George, Karen L., 137
 George, W. Lance, 657
 Geratz, J. Dieter, 582
 Gerding, Dale N., 58, 545, 560
 Gerlach, E. H., 633, 669
 Gervós, M. Santiago, 458
 Giamarellou, Helen, 534
 Gill, Charles J., 327
 Gill, M. John, 476
 Gille, Y., 144
 Girard, A. E., 118
 Girard, Dennis, 599
 Giuliano, Rubén A., 783
 Givan, Katherine F., 455
- Giasser, Lynne A., 510
 Glette, Johan, 354
 Gnarpe, Håkan, 179
 Godefroy, Isabelle, 168
 Godfrey, A. J., 382
 Goessens, Wil H. F., 575
 Goldman, Peter, 65
 Gombert, Myles E., 510
 Gooch, W. Manford, III, 502
 Goodman, Larry J., 504
 Gootz, Thomas D., 591
 Gordon, Y. Jerold, 522
 Goto, Sachiko, 98
 Gotoh, Akira, 754
 Goueffon, Y., 463
 Grappel, Sarah F., 694
 Greenman, Richard L., 16
 Griffin, Paul E., 33
 Gropen, Toby I., 522
 Grossman, Dena M., 690
 Gruft, Howard, 137
 Guay, David R., 306
 Guenther, Sharon H., 4
 Guerrant, Richard L., 653
 Gutterman, Deborah A., 16
 Guymon, L. F., 767
- Halcomb, William W., 20
 Hall, Dennis, 571
 Hall, Michael J., 607
 Haller, Ingo, 125
 Halstenson, C. E., 128
 Halstenson, Charles E., 433, 603
 Hamilton-Miller, J. M. T., 276
 Hammer, Mark C., 33
 Hansen, Alfred R., 301
 Hansen, Chad S., 301
 Hantz, O., 242
 Harcus, Jane L., 571
 Harding, Stuart M., 78, 344
 Harris, Betty, 162
 Harris, Cynthia, 560
 Harrison, Lester I., 301
 Hashizume, Terutaka, 148
 Haskell, Suzanne L., 599
 Hastie, Annette T., 673
 Hayden, Frederick G., 53
 Hector, Richard F., 596
 Heessen, Frans W. A., 123
 Herbst, John J., 630
 Hersh, Evan M., 366
 Hewlett, Erik L., 571
 Higgins, Michael L., 673
 Hindler, Janet A., 781
 Hirata, Takahiro, 148, 348
 Hoeprich, Paul D., 339
 Holmes, King K., 390
 Hooper, David C., 586
 Hopen, Gunnar, 354
 Hopfer, R. L., 387
 Hopfer, Roy L., 366
 Horaus, Thea, 289
 Hughes, Carolyn E., 560, 596
 Humbert, G., 638
 Hunajti, Abdelrahman A., 173
- Ikeda, Chieko, 221
 Inaba, Hitoshi, 88
 Inoue, Hiroshi, 146
 Inoue, Matsuhisa, 362

- Isono, Midori, 131
Ito, Masahiko, 515
- Jackson, David B., 591
Jacobs, Michael R., 527
Jacoby, Irving, 626
Jacyk, William R., 306
Jakas, Dalia R., 694
James, Philip R., 735
Jenkin, H. M., 772
Johnson, Elizabeth M., 1
Johnson, Jonas, 473
Johnson, Randall K., 622
Johnson, Steven R., 296
Johnston, Ralph W., 205
Jones, R. N., 633
Jones, Ronald N., 392, 669, 710, 775
Jordan, A. B., 37
Jorgensen, James H., 283
Juliano, R. L., 387
Juliano, Rudolph L., 366
- Kabir, Iqbal, 643
Kamimura, Toshiaki, 98
Kanzaki, Masako, 385
Kaplan, Raymond L., 504
Katz, Ehud, 195
Katz, W., 253
Keane, W. F., 128
Keane, William F., 433
Kern, Earl R., 553
Kesado, Tadataka, 131
Kim, H., 45
King, John W., 770
Kingsbury, W. D., 373
Kirkpatrick, James, 7
Klein, Robert S., 292
Klinger, Jeffrey D., 279
Knaus, Edward E., 476
Knight, Paul R., 719
Knight, Vernon, 729
Kobasa, William D., 683
Koeppel, P., 105
Kojo, Hitoshi, 98
Kolattukudy, Pappachan E., 173
Konno, Masatoshi, 754
Konopińska, Danuta, 134
Kosuzume, Hiroshi, 88
Koyama, Masaru, 221
Kramer, Michael J., 729
Kramer, William G., 62
Kreeft, John H., 83
Kueppers, Friedrich, 673
Kunz, Samuel, 311
Kuroki, Tohru, 146
Kuwahara, Shogo, 98
Kwan, S., 382
- Labthavikul, Pornpen, 687
Lacroix, Jean-Michel, 662
Lambe, Catherine U., 191
Lamothe, François, 662
Larsson, A., 524
Lastra, C. Fernandez, 458
Lawee, David, 455
Lechi, A., 760
Lefler, Eli, 450
Leguy, F., 638
Leive, Loretta, 539
Lentino, Joseph R., 778
Leroy, A., 638
Levi, Joe U., 358
Levison, Matthew E., 683
- Lewis, John C., 380
Lewis, Michael R., 422
Li, Edwin L. F., 455
Lin, C., 45
Lind, I., 767
Lipsky, James J., 380
Livelli, Thomas J., 247
Livermore, David M., 268
Lloyd, William J., 607
Lode, H., 105
Lolekha, Somsak, 273
Lopez-Berestein, G., 387
Lopez-Berestein, Gabriel, 366
Lorian, Victor, 311
Lowy, Franklin D., 375
Luft, Friedrich C., 513
Lukehart, Shelia A., 390
Lundback, Annika, 179
Lynch, J. E., 118
Lyon, James, 473
- Maclean, Ian W., 187
Mader, Jon T., 139
Mageau, Richard P., 205
Maimone, F., 499
Malewicz, B., 772
Mandel, Neil, 109
Manian, Albert A., 571
Margalith, Eva., 195
Marino, E. L., 458
Marino, John, 527
Marks, Melvin I., 212
Marlowe, Steve, 553
Marr, J. Joseph, 292
Marsh, Y. Vivienne, 563
Martin, Albert R., 626
Martinez, Octavio V., 358
Maruyama, Tsutomu, 385
Maskell, Jeffrey P., 268
Matsen, John M., 630
Matsui, Hidefumi, 221
Matsumoto, Yoshimi, 98
Matthews, Thomas R., 563
Mattie, H., 263
Matzke, G. R., 128
Matzke, Gary R., 433, 603
McAnally, Thomas P., 422
McClatchey, Kenneth D., 491
McCormick, Ellen M., 336
McCracken, George H., Jr., 29, 427, 556
McFarland, James W., 226
McGory, Robert W., 433
McGuirt, Paul V., 507
McHugh, Gail L., 586
McKeough, M. B., 10
McKerlie, M. Louese, 646
McLafferty, Martha A., 65
Meatherall, Robert C., 306
Meddens, M. J. M., 263
Mehta, Kapil, 366
Mehta, R., 387
Mehta, Reeta, 366
Mehta, R. J., 373
Merigan, Thomas C., 25
Merry, Joanne M., 339
Meshnick, Steven R., 286
Metzger, Linda S., 216
Michel, M. F., 575
Miller, Heather, 411
Miller, Richard L., 191
Miller, Wayne H., 191
Mills, K., 387
Mine, Yasuhiro, 98
- Mirabelli, Christopher K., 622
Mitsuhashi, Susumu, 362
Miyakawa, Isao, 146
Mobley, Harry L. T., 157
Mochizuki, Hidenori, 88
Moellering, R. C., Jr., 331, 401
Moellering, Robert C., Jr., 398
Molendijk, Lucy, 234
Momsen, M., 772
Montay, G., 463
Moody, Julia A., 545, 560
Moretti, A., 666
Morgan, S. L., 37
Morgant, Catherine, 618
Mori, Norimasa, 146
Morrison, Joan O., 725
Muder, Robert R., 473
Muller, G., 281
Muramatsu, Masatake, 385
Murray, Barbara E., 398
Murray, Patrick R., 368
Muytjens, Harry L., 123
Muzalewski, Feliks, 134
Myers, Carolyn M., 579
Myers, William F., 690
- Nagel, Arthur A., 113
Nakagawa, Keiichi, 221
Nakatsuru, Naoki, 221
Nelson, Donald J., 292
Nelson, Erica, 522
Nesburn, Anthony B., 522
Neu, Harold C., 319, 529, 687
Neut, C., 764
Nguyen, Khoi B., 455
Nicoletti, M., 9
Nierste, David M., 513
Niles, Ann C., 368
Noguchi, Takashi, 221
Northrop, Dexter B., 479
Novick, William J., Jr., 380
- Ober, Robert E., 301
Odio, Carla, 427, 556
Ogilvie, Richard I., 83
Ohmae, Kenichi, 385
Ohnishi, Haruo, 88
Okafor, Josephine I., 413
Olsen, Kurt D., 29
Ooka, T., 242
Opal, Stephen, 7
Otto, Michael J., 566
Overall, James C., Jr., 553
Overturf, Gary D., 258
- Panosian, Claire B., 655
Parker, Bruce C., 137
Parr, Thomas R., Jr., 747
Parrillo, Patricia, 778
Passarella, E., 760
Pasticci, M. B., 666
Patel, Indravadan H., 438
Pattison, Fred L. M., 455
Pattyn, Stefaan R., 518
Pauluzzi, S., 666
Pearson, Richard D., 571
Penn, Robert L., 770
Penner, Brian, 306
Pennington, James E., 49
Perea, Evelio J., 342
Perna, Pasquale, 182
Perry, Helen C., 247
Peters, Andre C. B., 522
- Peterson, Lance R., 58, 545, 560, 596
Pfaller, Michael A., 368
Phillips, Lillian, 694
Pichoud, C., 242
Pickering, Larry K., 62
Pirie, Donald K., 226
Pitkin, Donald, 694
Piziak, Myron V., 7
Plotkin, S. A., 417
Pohlod, Donald J., 377
Pollack, Simeon, 375
Pollet, Dirk E., 783
Porter, F. D., 157
Portnoy, David, 455
Potten, Michael R., 1
Preblud, S. R., 417
Preblud, Stephen R., 327
Proctor, E. A., 417
Provoost, Abraham P., 497
Prusoff, William H., 566
Pugsley, Mary P., 494
Pushkarskaya, Nina L., 53
- Radika, Kesavan, 479
Rahaman, M. Mujibur, 643
Raimondi, M. G., 760
Rector, Tim M., 582
Reed, Michael D., 579
Retsema, J. A., 118
Retsema, James A., 113, 226
Richardson, Malcolm D., 1
Ripa, S., 666
Rohlfing, Stephen R., 301
Romanowski, Barbara, 455
Romaru, Annette, 618
Romond, C., 764
Ronald, Allan R., 187
Roquet, F., 463
Rosano, Thomas G., 336
Rosen, Barry P., 157
Rosenberg, Martin, 622
Ross, Janette, 785
Rotschafer, John C., 785
Rubin, Robert H., 626
Ruggiero, Giuseppe, 182
Rusconi, Franca, 395
Ryder, Neil S., 483
- Sabados, Joyce, 646
Saino, Yushi, 362
Sakata, Yasutaka, 29
Sakuma, Takashi, 742
Salem, Nanda G., 603
Samuel, John, 476
Sandberg, Sverre, 354
Sanders, Christine C., 494
Sanders, W. Eugene, Jr., 494
Sanfeliu, Isabel, 706
Saravolatz, Louis D., 377
Sattler, Fred R., 153
Sawada, Takuo, 385
Sawai, Tetsuo, 148, 348
Saxon, Barbara A., 603
Schaberg, Dennis R., 491
Scharpé, Simon L., 783
Schelkly, W., 118
Schentag, Jerome J., 201
Schiff, Jill B., 49
Schlepushkin, Anatoli N., 53
Schnipper, Lowell E., 553
Schultz, Robert W., 201
Schuppman, Dietrich, 301
Schuster, F. L., 109

- Schwab, Bernard, 205
 Sciavolino, Frank C., 113
 Scribner, Ronald K., 212
 Seidl, Gunther, 483
 Selden, Robert F., 4
 Seto, Kenji, 385
 Shafer, W. M., 767
 Shatzman, Allan R., 622
 Shaw, James E., 507
 Sherris, John C., 591
 Shields, David S., 653
 Shigeta, Shiro, 515
 Shikuma, Cecilia, 258
 Shipley, Patricia L., 653
 Shlaes, David M., 527
 Siegel, Scott A., 566
 Siemens, A. W., 438
 Silver, Simon, 157
 Sirinavin, Sayomporn, 273
 Slaney, Leslie A., 187
 Smith, C. W., 37
 Smith, Gaylord, 286
 Smith, Margaret C. M., 446
 Smith, Raymond P., 33, 488
 Sobel, J. D., 281
 Solberg, Claus O., 354
 Solliday, JoAnne, 532
 Somerville, Peter J., 83
 Sommers, De Klerk, 344
 Sommers, H. M., 633
 Sommers, Herbert M., 669
 Southern, J. A., 253
 Spauling, P. F., 767
 Spencer, G. R., 638
 Spruance, S. L., 10
 Spruance, Spotswood L., 553
 St. Clair, Marty H., 191
 Stachowski, Michael, 778
 Starr, S. E., 417
 Steigbigel, Neal H., 375
 Stern, Robert C., 579
 Stevens, David A., 450
 Storrs, Bruce, 502
 Strikas, Raymond, 778
 Stutman, Harris R., 212
 Sugerman, A. Arthur, 93
 Sugihara, J. G., 438
 Sun, Chong-Son, 729
 Sutphen, Nancy, 33
 Sutton, J. P., 37
 Swabb, Edward A., 93
 Swartz, Mark D., 586
 Swartz, Morton N., 586
 Szoka, Francis, 655
 Tagari, Gioula, 534
 Takafuji, Ernest, 7
 Takahashi, Toshio, 385
 Tannenbaum, Charles S., 673
 Tao, Pei-Zhen, 524
 Taylor, Dean P., 622
 Telesetsky, Stephanie, 539
 Terakado, Nobuyuki, 385
 TeStrake, Diane, 413
 Thearle, Patricia, 473
 Thomas, Marion L., 29, 427, 556
 Thompson, J., 263
 Thompson, Robert L., 4
 Thornsberry, C., 633
 Thornsberry, Clyde, 392, 710
 Threlkeld, Norma, 556
 Ti, Teow-Yee, 83
 Tidwell, Richard R., 582
 Tiemens, Karen M., 653
 Tigaud, S., 144
 Tocci, Michael J., 247
 Tofte, Robert W., 532, 785
 Tolkoff-Rubin, Nina E., 626
 Tramont, Edmund, 7
 Trenholme, Gordon M., 504
 Trepo, C., 242
 Trevisán, Alejandro R., 659
 Troke, Peter F., 483
 Trousdale, Melvin D., 522
 Tuazon, Carmelita U., 411
 Tung, Charlotte, 586
 Tyrrell, D. Lorne, 476
 Ubukata, Kimiko, 754
 Ueno, Kazue, 131
 Utili, Riccardo, 182
 Vaara, M., 701
 Valenta, J., 373
 Van Caekenberghe, Dirk L., 518
 Van Etta, Linda L., 58
 van Furth, R., 263
 Van Leeuwen, Willem B., 497
 van Raffe, M., 575
 Van Schalkwijk, Wim P., 497
 Van Wyk, Marieta, 344
 Vaxelaire, Juliane, 311
 Velo, G. P., 760
 Verbist, Ludo, 141, 783
 Verhaegen, Jan, 141
 Verpooten, Gert A., 783
 Viljanen, P., 701
 Vincent, P., 144
 Visscher, David W., 513
 Visudhipan, Pongsakdi, 273
 Vitvitski, L., 242
 Vosbeck, Klaus, 735
 Wagenvoort, Johan H. T., 497
 Walker, David H., 582
 Walker, Marion L., 502
 Walker, Naomi A., 513
 Walker, Richard I., 71
 Warnock, David W., 1
 Watanabe, Kunitomo, 131
 Weinbaum, George, 673
 Weinfeld, R. E., 438
 Weiss, Emilio, 71
 Welage, Lynda S., 201
 Welch, David F., 212
 Wennersten, Christine, 398
 Wenzel, Richard P., 4
 Westmacott, Donald, 607
 Wexler, Hannah, 162
 Wiebe, Leonard I., 476
 Williams, J. David, 268
 Williams, Peter E. O., 78, 344
 Williamson, Peter J., 1
 Wilson, Katharine J., 139
 Wilson, Mary E., 626
 Wilson, Samuel Z., 729
 Wise, R., 612
 Wissemann, Charles L., Jr., 690
 Wolfson, John S., 586
 Wong, E. G. C., 438
 Woodbury, Charles, 7
 Woods, D. R., 253
 Wright, Charlotte A., 408
 Wright, Donald N., 165
 Wu, David H., 488
 Wyde, Philip R., 729
 Wyler, David J., 655
 Yamaguchi, Akihito, 148, 348
 Yamashita, Naoko, 754
 Yamashita, Toyoko S., 579
 Yangco, Bienvenido G., 413
 Yano, Kuniichiro, 221
 Yeung, Tin-Chuen, 65
 Yoshinaga, Koji, 221
 Yu, Victor L., 473
 Zaffaroni, Giuseppe, 395
 Zak, Oto, 311
 Zimmermann, Willy, 735
 Zissis, Nicholas P., 534
 Zorzópulos, Jorge, 659
 Zuromskis, Peter, 626
 Zweig, Richard M., 16

SUBJECT INDEX

VOLUME 25

- AC-1370
mechanism of action, 88
phagocyte functions, 88
- Acanthamoeba* spp.
phenothiazone compounds, 109
- Acridine orange
K. pneumoniae R plasmid deletion, 659
- Acyclic nucleosides
9-(1,3-dihydroxy-2-propoxymethyl)
guanine, 563
- Acyclovir
antiviral-activity potentiation
polyene macrolides, 772
efficacy, 10
herpes simplex virus, 10
DNA fragment synthesis, 507
patient-initiated treatment, 553
penetration, 10
synergy with interferon, 515
topical therapy, 10
varicella-zoster virus, 515
- Adenine arabinoside
synergy with interferon, 515
varicella-zoster virus, 515
- Aerobic bacteria
erythromycin, 529
RU 28965, 529
- Amikacin
combinations
ceftazidime, 725
ceftiozime, 725
ceftioxime, 725
cystic fibrosis, 279
P. aeruginosa, 279
P. cepacia, 279
Enterobacteriaceae, 725
nephrotoxicity, 168
neutropenic-site rabbit model, 545
P. aeruginosa, 545
tubular reabsorption, 168
- Aminoglycosides
combinations
teichomycin, 411
vancomycin, 411
enterococci, 411
extraction from renal cortical tissue, 783
modification by enzymes
S. aureus, 754
S. epidermidis, 754
nephrotoxicity, 168
2'-O-nucleotidyltransferase activity, 234
P. aeruginosa, 488, 534
rat tissue
enzyme immunoassays, 497
resistance, 234
staphylococci, 411
synergy with β -lactams, 534
tubular reabsorption, 168
- Amoxicillin
combined with clavulanic acid, 276
urinary tract infections, 276, 626
- Amphotericin B
antifungal activity, 387
Aspergillus spp., 560
C. albicans infection, 366
combinations
antifungal agents, 560
rifampin, 560
leishmaniasis, 655
liposome encapsulated, 366, 387, 655
prophylaxis, 366
- Ampicillin
combinations
gentamicin, 408
comparative efficacy
pivmecillinam, 643
S. faecalis endocarditis, 408
shigellosis, 643
- Anaerobic bacteria
apalcillin, 162
cefoxitin, 764
cefpiramide, 162
ciprofloxacin, 342
clindamycin, 764
erythromycin, 529
metronidazole, 764
RU 28965, 529
- Animal viruses
halothane, 719
replication, 719
- Antifungal agents
Aspergillus spp., 560
combinations
amphotericin B, 560
rifampin, 560
- Antifungal azoles
Bay I 9139, 339
Bay n 7133, 339
- Antineoplastic agents
screening
E. coli genetically modified strain, 622
- Antiviral compounds
varicella-zoster virus susceptibility, 417
- Apalcillin
anaerobes, 162
comparative activity, 162
carbenicillin, 669
piperacillin, 669
pharmacokinetics
compared with piperacillin, 105
- 1- β -D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil
varicella-zoster virus, 742
- Arsenate
E. coli R factors, 157
- Aspergillus* spp.
amphotericin B, 560
antifungal agents, 560
rifampin, 560
- Azlocillin
comparative efficacy, 49
neutropenic-site rabbit model, 545
P. aeruginosa
drug combinations, 545
pneumonia, 49
pharmacokinetics
cystic fibrosis, 630
- Aztreonam
activity
alone, 212
in combination, 212
biliary tract disease, 358
combinations
amikacin, 279
cystic fibrosis, 279
gram-negative bacilli, 283
 β -lactams, 283
multiple resistance, 283
P. aeruginosa, 279
P. cepacia, 279
comparative efficacy, 49
excretion, 358
- immunology, 93
P. aeruginosa pneumonia, 49
pediatric patients, 212
syphilis, 390
- Bacillus megaterium*
copper toxicity, 650
siderophores, 650
- Bacitracin
coagulase-negative staphylococci, 502
S. aureus nasal carriers, 422
- Bacterial infections
cefmenoxime, 510
- Bacteriocins
B. fragilis, 253
- Bacteroides fragilis*
bacteriocins, 253
cephalosporins
 7α -methoxy, 131
 7β -methoxyiminoacetamido, 131
clavulanic acid, 662
 β -lactams, 662
synergy with gentamicin
clindamycin, 71
metronidazole, 71
penicillin, 71
- Bacteroides melaninogenicus*
synergy with gentamicin
clindamycin, 71
metronidazole, 71
penicillin, 71
- Basidiobolus* spp.
susceptibility, 413
- Bay I 9139
antifungal activity, 339
- Bay n 7133
antifungal activity, 339
high-pressure liquid chromatography, 596
- Bay o 9867
see ciprofloxacin
- Benzylpenicillin
probenecid interaction, 676
- Biliary tract disease
aztreonam excretion, 358
- Biophotometric methods
S. aureus intraphagocytic activity, 735
- Bordetella pertussis*
degraded strains, 537
resistance, 537
- Bromovinyl deoxyuridine
synergy with interferon, 515
varicella-zoster virus, 515
- (E)-5-(2-Bromovinyl)-2'-deoxyuridine
herpes simplex virus polypeptide synthesis, 566
- BW759U
DNA polymerases
cellular α , 191
herpes simplex virus induced, 191
triphosphate, 191
- Campylobacter fetus* subsp. *jejuni*
metronidazole, 145
niridazole, 145
- Campylobacter* spp.
ciprofloxacin, 504
- Candida albicans*
amphotericin B, 366

- clotrimazole, 450
econazole, 450
growth, 483
ketoconazole, 281, 450
miconazole, 450
naftifine, 483
neutropenic mice, 366
sterol biosynthesis, 483
susceptibility
 growth phase, 316
 ketoconazole, 316
 miconazole, 316
 tioconazole, 450
 vaginitis, 281
Candida spp.
 peptide transport, 373
 polyoxin, 373
Carbapenem derivatives
 SF2103A, 348
Carbenicillin
 comparative activity
 apalcillin, 669
 piperacillin, 669
 hemostasis, 153
Cardiopulmonary bypass surgery
 ceftriaxone levels, 37
Cefamandole
 cross-resistance
 methicillin, 666
 E. coli
 killing, 182
 phagocytosis, 182
Cefazolin
 urinary excretion
 furosemide, 618
 piretanide, 618
 water loading, 618
Cefmenoxime
 serious bacterial infections, 510
Cefoperazone
 penetration into surgical-wound drainage, 473
Ceforanide
 S. aureus endocarditis, 16
Cefotaxime
 kinetics
 effects of protein binding, 58
 susceptibility, 377
Cefotiam
 comparative efficacy
 cephalothin, 778
 dihydrochloride
 placental transfer, 147
 skin infections, 778
 soft tissue infections, 778
Cefoxitin
 anaerobic bacteria, 764
 comparative activity
 clindamycin, 764
 metronidazole, 764
 neutropenic-site rabbit model, 545
 P. aeruginosa, 545
Cefpiramide
 anaerobes, 162
 comparative activity, 162
 pharmacokinetics
 humans, 221
Cefsulodin
 cystic fibrosis, 4
 P. aeruginosa mutants, 382
 pharmacokinetics
 cystic fibrosis, 579
 single dose, 579
Ceftazidime
 combinations
 amikacin, 725
 clindamycin, 657
 gentamicin, 725
 distribution in ascitic fluid, 760
 Enterobacteriaceae, 725
 H. influenzae, 29
 meningitis
 efficacy, 29
 pharmacokinetics, 29
 nephrotoxicity in rats, 513
 P. aeruginosa mutants, 382
 pharmacokinetics
 decreased renal function, 785
 meningitis, 29
 normal subjects, 638
 renal insufficiency, 201
 uremic subjects, 638
 Pseudomonas spp., 395
 urinary tract infections, 395
Ceftizoxime
 combinations
 amikacin, 725
 gentamicin, 725, 770
 Enterobacteriaceae, 725
 high-pressure liquid chromatography, 336
 meningitis, 258
 neutropenic-site rabbit model, 545
 P. aeruginosa, 545, 770
 uremic patients, 336
Ceftriaxone
 amikacin, 725
 combinations
 gentamicin, 725
 Enterobacteriaceae, 725
 H. influenzae, 29
 kinetic disposition
 renal failure patients, 83
 levels in blood and tissue
 cardiopulmonary bypass surgery, 37
 meningitis
 efficacy, 29, 40
 pharmacokinetics
 meningitis, 29
 renal impairment, 438
Cefuroxime
 1-acetoxyethyl ester, 78
 axetil
 pharmacokinetics, 344
 meningitis, 273
Cephalosporinases
 P. maltophilia, 362
Cephalosporins
 aminothiazolyl α -methoxyimino, 710
 B. fragilis, 131
 cross-resistance
 cefamandole, 666
 methicillin, 666
 expanded spectrum
 SK&F 88070, 694
 HR810, 710
 7 α -methoxy, 131
 7 β -methoxyiminoacetamido, 131
 resistance
 Citrobacter spp., 591
Cephalothin
 comparative efficacy
 cefotiam, 778
 Enterobacteriaceae resistance, 725
 skin infections, 778
 soft tissue infections, 778
Cephems
 FK 027, 98
Chancroid
 H. ducreyi, 187
 tetracycline resistance, 187
Chlamydia trachomatis
 cinoxacin, 123
 ciprofloxacin, 123
 nalidixic acid, 123
 norfloxacin, 123
 pipemidic acid, 123
Chloramphenicol
 antagonism of β -lactams, 405
 comparative activity, 327
 detection, 205
 enzyme-linked immunoassay, 205
 K. pneumoniae, 405
 quantitation, 205
 Salmonella spp., 327
Chlorpromazine
 hydrochloride
 pathogenic amoebae, 109
 L. donovani, 571
Cinoxacin
 antibacterial activity, 633
 cross-resistance
 DJ6783, 775
 enoxacin, 775
 nalidixic acid, 775
 norfloxacin, 775
 oxolinic acid, 775
 C. trachomatis, 123
 resistant-population selection, 775
Ciprofloxacin
 anaerobic bacteria, 342
 antibacterial activity, 633
 Campylobacter spp., 504
 comparative activity, 319, 331, 518
 C. trachomatis, 123
 enteric pathogens, 504
 inoculum effect, 342
 medium effect, 342
 pH effect, 342
Citrobacter spp.
 cephalosporin resistance, 591
Clavulanic acid
 combined with amoxicillin
 urinary tract infections, 276
 combined with ticarcillin, 392
 β -lactam activity, 662
Clindamycin
 anaerobic bacteria, 764
 combined with ceftazidime
 antibacterial activity, 657
 comparative activity
 cefoxitin, 764
 synergy
 Bacteroides spp., 71
 gentamicin, 71
Clotrimazole
 C. albicans, 450
Cloxacillin
 staphylococcal endocarditis, 311
Common cold
 zinc gluconate, 20
Conidiobolus spp.
 susceptibility, 413
Contact-blocking virus inhibitor
 size, 646
 stability, 646
Copper
 B. megaterium, 560
 toxicity

- siderophores, 560
- Coumermycin
antibacterial activity, 687
- Cystic fibrosis
amikacin, 279
azlocillin pharmacokinetics, 630
aztreonam, 279
cefsulodin
 pharmacokinetics, 579
 sodium, 4
P. aeruginosa, 279
P. cepacia, 279
piperacillin, 279
ticarcillin, 279
- Cytomegalovirus
 α -interferon, 25
2'-nor-2'-deoxyguanosine, 247
retinitis, 25
- Desferrioxamine
urinary tract isolates, 375
- cis*-Diammineplatinum[II]-polyglutamic acid
T. congolense, 286
- Dibekacin
nephrotoxicity, 168
tubular reabsorption, 168
- 9-(1,3-Dihydroxy-2-propoxymethyl) guanine
herpes simplex virus, 563
 β -interferon, 563
- DJ6783
cross-resistance
 cinoxacin, 775
 enoxacin, 775
 nalidixic acid, 775
 norfloxacin, 775
 oxolinic acid, 775
resistant-population selection, 775
- DNA gyrase inhibitors
E. coli plasmid elimination, 586
- DNA polymerases
BW759U triphosphate, 191
cellular α , 191
hepatitis virus, 242
herpes simplex virus induced, 191
- Doxycycline
polymorphonuclear leukocytes, 354
- Econazole
C. albicans, 450
- Endocarditis
ampicillin, 408
cefazidime, 16
cloxacillin, 311
drug abusers, 16
gentamicin, 408
granulocytes, 263
mezlocillin, 408
S. aureus, 16
S. faecalis, 408
S. sanguis, 263
staphylococcal, 311
- Enoxacin
cross-resistance
 cinoxacin, 775
 DJ6783, 775
 nalidixic acid, 775
 norfloxacin, 775
 oxolinic acid, 775
resistant-population selection, 775
- Enteric pathogens
ciprofloxacin, 504
- Enterobacter aerogenes*
endocarditis
 gentamicin, 683
 mezlocillin, 683
 ticarcillin, 683
- Enterobacteria
 β -lactamases, 268
- Enterobacteriaceae*
amikacin, 725
ceftazidime, 725
ceftizoxime, 725
ceftriaxone, 725
cephalothin resistant, 725
gentamicin, 725
- Enterococci
aminoglycosides, 411
ribosomal resistance, 398
rifampin, 411
streptomycin, 398
susceptibility, 532
teichomycin, 411
vancomycin, 411
- Enzyme immunoassays
aminoglycosides
 rat tissue, 497
- Enzyme-linked immunoassays
competitive
 chloramphenicol, 205
- Enzymes
aminoglycoside modification, 754
S. aureus, 754
S. epidermidis, 754
- Erysipelas
swine
 E. rhusiopathiae resistance, 385
- Erysipelothrix rhusiopathiae*
chronic swine erysipelas, 385
resistance, 385
- Erythromycin
aerobic bacteria, 529
anaerobic bacteria, 529
comparative activity, 529
methylmalonyl-coenzyme A source, 173
synthesis from *S. erythraeus*, 173
- Escherichia coli*
cefamandole, 182
DNA gyrase inhibitors, 586
DNA repair mutants, 65
genetically modified strain
 antineoplastic-agent screening, 622
gentamicin, 182
killing, 182
meningitis
 mezlocillin pharmacokinetics, 427
 metronidazole, 65
 novobiocin, 586
 outer membrane permeability, 539
 phagocytosis, 182
 plasmid elimination, 586
 pMG110, 586
R factors
 arsenate, 157
 homology, 157
 tetracyclines, 539
 tetracycline transport, 446
- Exopolysaccharides
P. aeruginosa
 binding, 673
- Fludalanine
pentizidone combination
 comparative activity, 612
- Flumequine
fluorometric assays, 301
high-pressure liquid chromatography, 301
microbiological assays, 301
- Fluorinated piperaziny-substituted quinoline derivatives
comparative activity, 518
- Fluorometric assays
flumequine, 301
- Furosemide
cefazolin excretion in urine, 618
- Gentamicin
coagulase-negative staphylococci, 502
combinations
 ampicillin, 408
 ceftazidime, 725
 ceftizoxime, 725, 770
 ceftriaxone, 725
 mezlocillin, 408
E. coli
 killing, 182
 phagocytosis, 182
 elimination rate, 128
 clearance, 128
Enterobacteriaceae, 725
hemodialysis, 128
nephrotoxicity, 168
P. aeruginosa, 770
synergy
 B. fragilis, 71
 B. melaninogenicus, 71
 clindamycin, 71
 metronidazole, 71
 penicillin, 71
 tubular reabsorption, 168
- Gonorrhea
rosoxacin, 455
- Gram-negative bacteria
aztreonam, 283
 β -lactams, 283
multiple resistance, 283
polymyxin B nonapeptide, 701
- Granulocytes
S. sanguis endocarditis, 263
stimulation
 imipenem, 179
 MK 0791, 179
- Haemophilus ducreyi*
chancroid treatment, 187
 β -lactamase plasmid, 296
resistance
 plasmid mediated, 187
 tetracycline, 187
- Haemophilus influenzae*
multiply resistant
 susceptibility, 706
type b
 ceftazidime, 29
 ceftriaxone, 29
 chloramphenicol resistant, 29
 imipenem, 29
 β -lactams, 747
 mechanisms of resistance, 747
 meningitis, 29
- Halothane
animal virus replication, 719
- FK 027
antibacterial properties, 98

- Heavy-metal salts
susceptibility
 M. avium, 137
 M. intracellulare, 137
 M. scrofulaceum, 137
- Hemodialysis
gentamicin
 clearance, 128
 elimination rate, 128
tobramycin
 clearance, 128
 elimination rate, 128
- Hemostasis
carbenicillin, 153
mezlocillin, 153
placebo, 153
- Hepatitis virus
DNA polymerases, 242
human, 242
woodchuck, 242
- Herpes labialis
acyclovir, 553
patient-initiated treatment, 553
- Herpes simplex virus
acyclovir
 DNA fragment synthesis, 507
 efficacy, 10
 penetration, 10
 topical therapy, 10
(E)-5-(2-bromovinyl)-2'-deoxyuridine, 566
BW759U triphosphate, 191
9-(1,3-dihydroxy-2-propoxymethyl) guanine, 563
DNA polymerase induction, 191
 β -interferon, 563
(E)-5-(2-iodovinyl)-2'-deoxyuridine uptake, 476
lithium
 cell cultures, 522
 latent-infection reactivation in rabbits, 522
2'-nor-2'-deoxyguanosine, 238
orofacial infections in mice, 238
polypeptide synthesis, 566
SK&F 21681, 195
thymidine kinase
 guanosine analogs, 524
- High-pressure liquid chromatography
Bay n 7133, 596
ceftizoxime, 336
flumequine, 301
Sch 28191 levels, 45
- HR810
evaluation, 710
- Hypoprothrombinemia
1-methyl-5-thiotetrazole, 380
moxalactam, 380
- Imidazoles
C. albicans, 450
clotrimazole, 450
econazole, 450
ketocanazole, 450
miconazole, 450
tioconazole, 450
- Imipenem
bioactivity
 medium, 781
 temperature, 781
 time, 781
granulocyte function stimulation, 179
- H. influenzae*, 29
imipenem resistance, 491
meningitis
 efficacy, 29
 pharmacokinetics, 29
methicillin resistance
 S. aureus, 491
P. vulgaris β -lactamase, 149
subinhibitory concentrations, 491
- Influenza virus
inhibition
 interferon, 53
 ribavirin, 53
 rimantadine hydrochloride, 53
- Inosine analogs
Leishmania spp., 292
Trypanosoma spp., 292
- Interferon
aerosolized, 729
clearance, 729
cytomegalovirus retinitis, 25
9-(1,3-dihydroxy-2-propoxymethyl) guanine, 563
herpes simplex virus, 563
human leukocyte, 53
influenza virus inhibition, 53
pulmonary deposition, 729
synergy
 acyclovir, 515
 adenine arabinoside, 515
 bromovinyl deoxyuridine, 515
 phosphonoformic acid, 515
- Intraphagocytic activity
biophotometric method, 735
S. aureus, 735
(E)-5-(2-iodovinyl)-2'-deoxyuridine
herpes simplex virus, 476
uptake, 476
- Kanamycin
acetyltransferase
 enzymatic modification, 479
 resistance, 479
 V_{max}/K_m ratio, 479
- Ketoconazole
C. albicans
 growth phase, 316
 inhibition, 450
 killing, 450
 susceptibility, 316
 vaginitis, 281
pharmacokinetics
 influence of food, 1
- Klebsiella pneumoniae*
chloramphenicol, 405
 β -lactams, 405
R plasmids
 acridine orange, 659
 deletions, 659
- β -Lactamases
enterobacteria, 268
H. ducreyi, 296
inactivation, 348
mezlocillin-resistant *S. aureus*
 cell bound, 125
 extracellular, 125
N. gonorrhoeae, 296
P. aeruginosa mutants, 382
PSE-2, 268
P. vulgaris
 imipenem, 149
- SF2103A, 348
- β -Lactams
antagonism by chloramphenicol, 405
B. fragilis
 clavulanic acid, 662
combinations
 aztreonam, 283
 gram-negative bacilli, 283
 multiple resistance, 283
H. influenzae type b
 mechanism of resistance, 747
K. pneumoniae, 405
P. aeruginosa, 488, 534
synergy with aminoglycosides, 534
temocillin combinations, 142
- Lankacidin group antibiotics
side chain modifications, 226
- Leishmania donovani*
chlorpromazine, 571
- Leishmaniasis
amphotericin B, 655
- Leishmania* spp.
inosine analogs, 292
- Listeria monocytogenes*
meningitis
 mezlocillin pharmacokinetics, 427
- Lithium
herpes simplex virus
 cell cultures, 522
 latent-infection reactivation in rabbits, 522
- Meningitis
ceftazidime, 29
ceftizoxime, 258
ceftriaxone, 29, 40
cefuroxime, 273
E. coli, 427
imipenem, 29
L. monocytogenes, 427
mezlocillin pharmacokinetics, 427
traditional therapy, 40
- Methicillin
cross-resistance
 cefamandole, 666
 cephalosporins, 666
resistance
 imipenem, 491
 S. aureus, 491
- Methylmalonyl-coenzyme A
erythromycin synthesis, 173
S. erythraeus, 173
- 1-Methyl-5-thiotetrazole
hypoprothrombinemia, 380
- Metronidazole
anaerobic bacteria, 764
C. fetus subsp. *jejuni*, 145
comparative activity
 cefoxitin, 764
E. coli DNA repair mutants, 65
pharmacokinetics
 peritoneal dialysis patients, 306
synergy
 Bacteroides spp., 71
 gentamicin, 71
- Mezlocillin
combinations
 gentamicin, 408, 683
E. aerogenes endocarditis, 683
E. coli, 427
hemostasis, 153

- L. monocytogenes*, 427
 pharmacokinetics
 meningitis, 427
 newborn infants, 556
 pediatric oncology patients, 62
S. aureus resistance
 β -lactamase, 125
S. faecalis endocarditis, 408
 Miconazole
 C. albicans
 growth phase, 316
 inhibition, 450
 killing, 450
 susceptibility, 316
 Microbiological assays
 flumequine, 301
 Minocycline
 polymorphonuclear leukocytes, 354
 MK 0791
 granulocyte function stimulation, 179
 Moxalactam
 hypoprothrombinemia, 380
 pharmacokinetics
 elderly subjects, 33
Mycobacterium avium
 susceptibility
 heavy-metal salts, 137
 oxyanions, 137
Mycobacterium intracellulare
 susceptibility
 heavy-metal salts, 137
 oxyanions, 137
Mycobacterium scrofulaceum
 susceptibility
 heavy-metal salts, 137
 oxyanions, 137
- Naegleria fowleri*
 phenothiazine compounds, 109
 Naftifine
 C. albicans, 483
 Nalidixic acid
 antibacterial activity, 633
 cross-resistance
 cinoxacin, 775
 DJ6783, 775
 enoxacin, 775
 norfloxacin, 775
 oxolinic acid, 775
 C. trachomatis, 123
 resistant-population selection, 775
Neisseria gonorrhoeae
 envelope mutations
 antibiotic susceptibility, 767
 env-10, 767
 pyocin resistance, 767
 β -lactamase plasmid, 296
 probenecid, 676
 resistance trends, 7
Neisseria meningitidis
 nasopharyngeal carriers, 494
 Sch 29,482, 494
 Nephrotoxicity
 aminoglycosides, 168
 tubular reabsorption, 168
 Netilmicin
 nephrotoxicity, 168
 tubular reabsorption, 168
 Niridazole
 C. fetus subsp. *jejuni*, 145
Nocardia asteroides
 susceptibility, 165
- Nocardicin A
 synergy
 L-norvalyl-L-1-aminoethylphosphonic acid, 105
 2'-Nor-2'-deoxyguanosine
 cytomegalovirus, 247
 herpes simplex virus, 238
 Norfloxacin
 antibacterial activity, 633
 cross-resistance
 cinoxacin, 775
 DJ6783, 775
 enoxacin, 775
 nalidixic acid, 775
 oxolinic acid, 775
 C. trachomatis, 123
 resistant-population selection, 775
 L-Norvalyl-L-1-aminoethylphosphonic acid
 synergy
 nocardicin A, 607
 Novobiocin
 E. coli plasmid elimination, 586
 2'-O-Nucleotidyltransferase
 activity-aminoglycoside resistance relation, 234
- Oleandomycin
 derivatives
 biological activity, 113, 118
 synthesis, 113
 Osteomyelitis
 vancomycin
 concentrations in rabbit serum, 140
 Oxacillin
 coagulase-negative staphylococci, 502
 Oxolinic acid
 antibacterial activity, 633
 cross-resistance
 cinoxacin, 775
 DJ6783, 775
 enoxacin, 775
 nalidixic acid, 775
 norfloxacin, 775
 resistant-population selection, 775
 Oxyanions
 susceptibility
 M. avium, 137
 M. intracellulare, 137
 M. scrofulaceum, 137
 Oxytetracycline
 polymorphonuclear leukocytes, 354
- Pediatric patients
 aztreonam activity, 212
 Pefloxacin mesylate
 absorption, 463
 distribution, 463
 elimination, 463
 metabolic fate, 463
 Penicillin
 synergy
 Bacteroides spp., 71
 gentamicin, 71
 Pentizidone
 fludalanine combination
 comparative activity, 612
 Pharmacokinetics
 apalcillin, 105
 azlocillin, 607
 cefpiramide, 221
 cefsulodin, 579
- ceftazidime
 decreased renal function, 785
 H. influenzae meningitis, 29
 normal subjects, 638
 renal insufficiency, 201
 uremic subjects, 638
 ceftriaxone
 H. influenzae meningitis, 29
 renal impairment, 438
 cefuroxime axetil, 344
 imipenem, 29
 ketoconazole, 1
 metronidazole, 306
 mezlocillin
 meningitis, 427
 newborn infants, 556
 pediatric oncology patients, 62
 moxalactam, 33
 piperacillin, 105
 sultamicillin, 599
 vancomycin
 peritoneal dialysis, 603
 renal insufficiency, 433
- Phenothiazine compounds
 chlorpromazine hydrochloride, 109
 inhibition of pathogenic amoebae, 109
 trifluoperazine dihydrochloride, 109
 Phosphomycin
 pleural effusion patients, 458
 Phosphonoformic acid
 synergy with interferon, 515
 varicella-zoster virus, 515
 Pipemidic acid
 C. trachomatis, 123
 Piperacillin
 combinations
 amikacin, 279
 cystic fibrosis, 279
 P. aeruginosa, 279
 P. cepacia, 279
 comparative activity
 apalcillin, 669
 carbenicillin, 669
 comparative efficacy, 49
 P. aeruginosa
 mutants, 382
 pneumonia, 49
 pharmacokinetics
 compared with apalcillin, 105
 susceptibility, 377
 Piretanide
 cefazoline excretion in humans, 618
 Pivmecillinam
 comparative efficacy
 ampicillin, 643
 shigellosis, 643
 Placebo
 hemostasis, 153
 Plasmids
 DNA gyrase inhibitors, 586
 E. coli(pMG110), 586
 novobiocin, 586
 resistance
 acridine orange, 659
 deletions, 659
 host range, 289
 K. pneumoniae, 659
 streptococcal macrolide, 289
 S. wien epidemic history, 499
 Pleural effusion
 phosphomycin, 458
 Pneumonia
 azlocillin, 49

- aztreonam, 49
P. aeruginosa, 49
 piperacillin, 49
 ticarcillin, 49
 tobramycin, 49
- Polyene macrolides
 acyclovir activity, 772
- Polymorphonuclear leukocytes
 doxycycline, 354
 minocycline, 354
 oxytetracycline, 354
- Polymyxin B nonapeptide
 gram-negative bacteria, 701
- Polyoxin
 anti-*Candida* activity, 373
 peptide transport, 373
- Probenecid
 benzylpenicillin interaction, 676
N. gonorrhoeae, 676
- Protease inhibitors
 amidine type, 582
R. rickettsii, 582
- Protein binding
 cefotaxime kinetics, 58
- Proteus vulgaris*
 β -lactamase
 imipenem, 149
- Pseudomonas aeruginosa*
 amikacin, 279, 545
 aminoglycosides, 488, 534
 azlocillin, 49, 545
 aztreonam, 49, 279
 ceftazidime, 382
 ceftazidime, 382
 ceftizoxime, 545, 770
 cystic fibrosis, 279
 exopolysaccharide
 binding, 673
 gentamicin, 770
 β -lactamase, 382
 β -lactams, 488, 534
 mutants, 382
 neutropenic-site rabbit model, 545
 piperacillin, 49, 279, 382
 pneumonia, 49
 ticarcillin, 49, 279
 tobramycin, 49
- Pseudomonas cepacia*
 amikacin, 279
 aztreonam, 279
 cystic fibrosis, 279
 piperacillin, 279
 ticarcillin, 279
- Pseudomonas maltophilia*
 cephalosporinase, 362
- Pseudomonas* spp.
 ceftazidime, 395
 urinary tract infections, 395
- Pyocins
N. gonorrhoeae resistance, 767
- Quinolone carboxylic acid compounds
 ciprofloxacin, 319, 331
- Renal enzyme inhibitors
 MK 0791, 179
- Renal insufficiency
 pharmacokinetics
 ceftazidime, 201
 ceftriaxone, 438
 vancomycin, 433
- Resistance
N. gonorrhoeae, 7
- Retinitis
 cytomegalovirus, 25
 α -interferon, 25
- R factors
E. coli
 arsenate, 157
 homology, 157
- Ribavirin
 influenza virus inhibition, 53
- Rickettsia rickettsii*
 cell injury, 582
 protease inhibitors, 582
- Rifampin
Aspergillus spp., 560
 combinations
 amphotericin B, 560
 antifungal agents, 560
 teichomycin, 411
 vancomycin, 411
 enterococci, 411
S. aureus nasal carriers, 422
 staphylococci, 411
- Rimantadine hydrochloride
 influenza virus inhibition, 53
- Rochalimaea quintana*
 susceptibility patterns, 690
 trench fever, 690
- Rosoxacin
 gonorrhea, 455
- RU 28965
 aerobic bacteria, 529
 anaerobic bacteria, 529
 comparative activity, 529
- Salmonella* spp.
 chloramphenicol, 327
- Salmonella wien*
 epidemic history, 499
 plasmid stability, 499
- Sch 28191
 high-pressure liquid chromatography, 45
 levels in biological fluids, 45
- Sch 29,482
N. meningitidis nasopharyngeal carriers, 494
- SF2103A
 β -lactamase inactivation, 348
- Shigella flexneri*
 sulfamethoxazole-trimethoprim resistance, 653
- Shigellosis
 ampicillin, 643
 pivmecillinam, 643
- Siderophores
B. megaterium, 560
 copper toxicity enhancement, 560
- SK&F 21681
 herpes simplex virus, 191
- SK&F 88070
 antimicrobial activity, 694
- Skin infections
 cefotiam, 778
 cephalothin, 778
- SM-1652
 see cefpiramide
- Soft tissue infections
 cefotiam, 778
 cephalothin, 778
- Sparsomycin
 nontoxic analogs
 hydrophobic sulfoxide substituent, 443
 puromycin, 443
- Staphylococci
 aminoglycosides, 411
 cloxacillin, 311
 coagulase negative
 bacitracin, 502
 gentamicin, 502
 oxacillin, 502
 streptomycin, 502
 vancomycin, 502
 endocarditis, 311
 rifampin, 411
 teichomycin, 411
 vancomycin, 411
- Staphylococcus aureus*
 aminoglycoside-modifying enzyme, 754
 biophotometric method, 735
 ceforanide, 16
 endocarditis, 16
 intraphagocytic activity, 735
 mezlocillin resistance
 β -lactamase, 125
 nasal carriers
 bacitracin, 422
 rifampin, 422
 resistance
 imipenem, 491
 methicillin, 491
 tolerance detection, 571
- Staphylococcus epidermidis*
 aminoglycoside-modifying enzyme, 754
- Streptococci
 resistance plasmids, 289
- Streptococcus faecalis*
 ampicillin, 408
 gentamicin, 408
 endocarditis, 408
 mezlocillin, 408
- Streptococcus sanguis*
 endocarditis, 263
 granulocytes, 263
 vancomycin resistance, 527
- Streptomyces erythreus*
 erythromycin synthesis, 173
 methylmalonyl-coenzyme A, 173
- Streptomyces fradiae*
 carbon incorporation
 ty lactone, 216
- Streptomycin
 coagulase-negative staphylococci, 502
 enterococci, 398
 ribosomal resistance, 398
- Sulfamethoxazole
 combined with trimethoprim, 653
- Sulfamethoxazole-trimethoprim
S. flexneri resistance, 653
- Sultamicillin
 pharmacokinetics, 599
- Surgical wounds
 cefoperazone penetration, 473
- Syphilis
 aztreonam, 390
- Teichomycin
 combinations
 aminoglycosides, 411
 rifampin, 411
 enterococci, 411
 staphylococci, 411

- Temocillin
combined with other β -lactams, 142
- Tetracyclines
chancroid treatment, 187
doxycycline, 354
E. coli outer membrane permeability, 539
H. ducreyi resistance, 187
hydrophobicity, 539
minocycline, 354
oxytetracycline, 354
polymorphonuclear leukocytes, 354
transport into *E. coli*, 446
- Ticarcillin
combinations
amikacin, 279
clavulanic acid, 392
cystic fibrosis, 279
gentamicin, 683
P. aeruginosa, 279
P. cepacia, 279
comparative efficacy, 49
E. aerogenes endocarditis, 683
P. aeruginosa pneumonia, 49
- Tioconazole
C. albicans, 450
- Tobramycin
clearance, 128
comparative efficacy, 49
elimination rate, 128
hemodialysis, 128
P. aeruginosa pneumonia, 49
susceptibility, 377
- Trench fever
R. quintana
susceptibility patterns, 690
- Trifluoperazine dihydrochloride
pathogenic amoebae, 109
- Trimethoprim
combined with sulfamethoxazole, 653
- Trypanosoma congolense*
cis-diammineplatinum[II]-poly-glutamic acid, 286
- Trypanosoma* spp.
inosine analogs, 292
- Tuftsia
analogs, 134
antibacterial properties, 134
- Tylactone
carbon incorporation
amino acid derived, 216
S. fradiae, 216
- U-63196E
comparative activity, 401
- Urinary tract infections
amoxicillin, 626
amoxicillin-clavulanic acid, 276
ceftazidime, 395
desferrioxamine, 375
Pseudomonas spp., 395
- Vaginitis
C. albicans, 281
ketoconazole, 281
- Vancomycin
coagulase-negative staphylococci, 502
combinations
aminoglycosides, 411
rifampin, 411
enterococci, 411
osteomyelitis
concentrations in rabbit serum, 140
pharmacokinetics
peritoneal dialysis, 603
renal insufficiency, 433
S. sanguis resistance, 527
staphylococci, 411
- Varicella-zoster virus
acyclovir, 515
adenine arabinoside, 515
1- β -D-arabinofuranosyl-*E*-5-(2-bromovinyl)uracil, 742
bromovinyl deoxyuridine, 515
interferon, 515
phosphonoformic acid, 515
susceptibility, 417
- WIN 49375
susceptibility, 377
- Zinc gluconate
common cold, 20
double-blind study, 20

